Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, December 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 802 followers.

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal | SpringerLink https://t.co/JHOYiBui68

10 Dec 2019

Reply Repost Favourite

#HealthEconJA Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal https://t.co/23MiTA88dI

09 Dec 2019

Reply Repost Favourite